Dr. Reddy’s announced the launch of AVIGAN (Favipiravir) 200 mg Tablets in India. The launch is part of the global licensing agreement with FUJIFILM Toyama Chemical Co. Ltd. that grants Dr. Reddy’s the exclusive rights to manufacture, sell and distribute AVIGAN (Favipiravir) 200 mg Tablets in India. AVIGAN (Favipiravir) has been approved by the Drugs…
Pharma major Lupin Limited announced the launch of its Favipiravir in India under the brand name Covihalt for the treatment of mild to moderate COVID-19. Favipiravir has received authorization from the Drug Controller General of India (DCGI) for emergency use, the company mentioned in its press note. Lupin’s Covihalt dosage strength has been developed keeping…
Cipla Limited announced that it has been granted regulatory approval by the Drug Controller General of India (DCGI) for the launch of Favipiravir in the country under the brand name Ciplenza. The accelerated approval for manufacturing and marketing of the drug is aimed at meeting the urgent and unmet medical need for COVID-19 treatment options…
Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, announced that it has commenced a Post Marketing Surveillance (PMS) study on FabiFlu to closely monitor the efficacy and safety of the drug in 1000 patients that are prescribed with the oral antiviral, as part of an open label, multicenter, single arm study. Further, Glenmark has announced…
Dr Reddy’s Laboratories Ltd, announced that it has partnered with FUJIFILM Corporation through FUJIFILM Toyama Chemical Co. Ltd. and Global Response Aid for the development, manufacture and sales of Avigan Tablets (generic name: favipiravir), a potential treatment of COVID-19. Under the tripartite agreement signed on 30th June 2020, FUJIFILM grants Dr. Reddy’s the exclusive rights…
Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, announced the launch of antiviral drug Favipiravir (brand name FabiFlu) for the treatment of mild to moderate COVID-19 patients. Glenmark has received manufacturing and marketing approval from India’s drug regulator, making FabiFlu the first oral Favipiravir-approved medication in India for the treatment of COVID-19, the company said.…
Glenmark Pharmaceuticals, a research-led integrated global pharmaceutical company, announced that it has initiated Phase 3 clinical trials in India on Antiviral tablet Favipiravir, for which it received approval from India’s drug regulator DCGI in late April. Glenmark claims to be the first company in India to initiate Phase 3 clinical trials on Favipiravir for COVID-19…